September 24, 2012
Athersys CEO to Present on September 24, 2012 at the Noble Financial Life Sciences Exposition
Gil Van Bokkelen, Chairman and Chief Executive Officer of Athersys, Inc. (ATHX) will present at the Noble Financial Capital Markets Life Sciences Exposition, a conference focused on therapeutic drug development including regenerative medicine, immunotherapy, and targeted oncology. The presentation is scheduled as follows:
|Date:||Monday, September 24, 2012|
|Time:||1:00 pm ET|
|Location:||Hotel Zero Degrees, Stamford, CT|
|Live Webcast:||www.athersys.com under ‘Upcoming Events’ or directly athttp://noble.mediasite.com/mediasite/Play/a16ce152334c4a6cb58ca052cb6f7b0f1d|
A replay of the webcast will be available approximately 24 hours after the presentation and archived for 14 days at the aforementioned URLs.
Athersys is a clinical stage biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem(R) cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product platform for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas. The Company currently has several clinical stage programs involving MultiStem, including for treating inflammatory bowel disease, ischemic stroke, damage caused by myocardial infarction, and for the prevention of graft-versus-host disease. Athersys has also developed a diverse portfolio that includes other technologies and product development opportunities, and has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products. More information is available atwww.athersys.com.
The Athersys, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4548
Please read our Full Disclaimer pertaining to this article.